Abstract: The present invention relates to: an anti-fibroblast growth factor receptor 3 (FGFR3) antibody or antigen-binding fragment thereof; a nucleic acid encoding same; a recombinant expression vector comprising the nucleic acid; a host cell transfected with the recombinant expression vector; a method for producing the antibody or antigen-binding fragment thereof; a bispecific or multispecific antibody comprising the antibody or antigen-binding fragment thereof; an immune cell-engaging bispecific or multispecific antibody comprising an scFv comprising an scFv of the antibody and a second binding domain comprising at least one scFv of an antibody that binds to an immune cell-activating antigen; an antibody-drug conjugate (ADC) in which the antibody or the antigen-binding fragment thereof is bound to a drug; a chimeric antigen receptor (CAR) comprising the scFv of the anti-FGFR3 antibody as an antigen-binding site of an extracellular domain; an immune cell having the chimeric antigen receptor introduced thereinto; a c

Abstract: The present invention relates to an anti-c-Met antibody that is cross-reactive to human and mouse c-Met, and a use thereof and, more specifically, to: an anti-c-Met antibody or an antigen-binding fragment thereof; a bispecific antibody or an antibody-drug conjugate comprising the antibody or an antigen-binding fragment thereof; a pharmaceutical composition for preventing or treating cancer, comprising same; a nucleic acid coding for the antibody or an antigen-binding fragment thereof; a vector and a host cell comprising the nucleic acid; a method for preparing an anti-c-Met antibody or an antigen-binding fragment thereof by using same; and a co-administered cancer treatment composition containing the anti-c-Met antibody or an antigen-binding fragment thereof and another additional cancer treatment agent.

Abstract: The present disclosure relates to an antibody binding to Neuropilin 1 (NRP1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for preparing the antibody or the antigen-binding fragment thereof, an antibody-drug conjugate comprising the antibody or the antigen-binding fragment thereof, and a composition thereof for preventing or treating a cancer.

Abstract: There are provided a method named Tat-associated protein engineering (TAPE), of screening a target protein having higher solubility and excellent thermostability, in particular, an immunoglobulin variable domain (VH or VL) derived from human germ cells, by preparing a gene construct where the target protein and an antibiotic-resistant protein are linked to a Tat signal sequence, and then expressing this within E. coli, and human or engineered VH and VL domain antibodies and human or engineered VH and VL domain antibody scaffolds having solubility and excellent thermostability, which are screened by the TAPE method. There are also provided a library including random CDR sequences in the human or engineered VH or VL domain antibody scaffold screened by the TAPE method, and a preparing method thereof. There are also provided a VH or VL domain antibody having binding ability to the target protein screened by using the library, and a pharmaceutical composition including the domain antibody.

Abstract: The present disclosure relates to an antibody binding to Neuropilin 1 (NRP1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for preparing the antibody or the antigen-binding fragment thereof, an antibody-drug conjugate comprising the antibody or the antigen-binding fragment thereof, and a composition thereof for preventing or treating a cancer.

Abstract: There are provided a method named Tat-associated protein engineering (TAPE), of screening a target protein having higher solubility and excellent thermostability, in particular, an immunoglobulin variable domain (VH or VL) derived from human germ cells, by preparing a gene construct where the target protein and an antibiotic-resistant protein are linked to a Tat signal sequence, and then expressing this within E. coli, and human or engineered VH and VL domain antibodies and human or engineered VH and VL domain antibody scaffolds having solubility and excellent thermostability, which are screened by the TAPE method. There are also provided a library including random CDR sequences in the human or engineered VH or VL domain antibody scaffold screened by the TAPE method, and a preparing method thereof. There are also provided a VH or VL domain antibody having binding ability to the target protein screened by using the library, and a pharmaceutical composition including the domain antibody.

Abstract: Provided are a full genome DNA of a human cytomegalovirus (HCMV) strain JHC isolated from Korean patients and open reading frames (ORFS) thereof and, more particularly, UL1, UL119 and RL6.

Abstract: A linear double-stranded RNA molecule, which comprises two or more consecutively or convergently linked short interfering RNAs (siRNAs) each reducing the expression of one of different target genes, and a recombinant expression vector comprising double-stranded DNA sequence expressing the linear double-stranded RNA molecule are provided. The linear double-stranded RNA molecule or the recombinant expression vector is useful for a method of reducing expression of target genes in a cell, the method comprising introducing the linear double-stranded RNA molecule or the recombinant expression vector into the cell, whereby the encoded siRNAs target different genes and reduce expression of the target genes. It was also proved that effective gene silencing activity can be induced when each siRNA unit within the linear double-stranded RNA molecule has 18 to 24 nucleotides and, additionally, the gene silencing activity is not affected by inverted orientation of an siRNA.

Abstract: The present invention relates to a pharmaceutical composition for the inhibition of cancer metastasis, more precisely, a novel pharmaceutical composition against cancer metastasis comprising lipocalin 2 protein, a gene encoding the protein, an expression vector containing the gene or cells transfected with the expression vector as an effective ingredient, a method for the inhibition of cancer metastasis using the composition, a diagnostic kit for the prediction of cancer metastasis, a method for the selection of a metastasis risk group using the kit, a novel pharmaceutical composition for the inhibition of cancer growth and a method for the inhibition of cancer growth using the same. The pharmaceutical composition of the present invention specifically inhibits cancer metastasis, so that it can improve the effect of cancer treatment dramatically.

Abstract: A method for enhancing the serum stability and lowering the immunostimulatory property of a small interfering ribonucleic acid (siRNA) which mediates RNA interference (RNAi) against a viral gene expression of hepatitis B virus (HBV) or hepatitis C virus (HCV) is provided.

Abstract: The present invention relates to an LK8-Fc fusion protein, which has increased angiogenesis inhibitory activity and in vivo stability. More specifically, relates to an LK8-Fc fusion protein in which an LK8 protein having angiogenesis inhibitory activity is fused with the Fc region of human immunoglobulin IgG1, as well as a composition for treating cancer, which contains the fusion protein. The LK8-Fc fusion protein has not only angiogenesis inhibitory activity leading to anticancer and metastasis inhibitory activities, but also a very long in vivo half-life, and thus can be used as a more efficient and economic cancer therapeutic agent or cancer inhibitor.

Abstract: The present invention relates to a method for reducing the fucose content of a recombinant protein, which comprises expressing in an animal cell the recombinant protein and FUCA1, an FUCA1 mutant, FUCA2, or a fragment of FUT8 localization domain; or with a fusion protein of a fragment of FUT8 localization domain and a fragment of FUCA1, a FUCA1 mutant or FUCA2. Therefore, the antibody expressed according to the method of the present invention exhibits a reduced fucose content in their Fc regions, which leads to the improvement in the therapeutic effect thereof.

Abstract: The present invention relates to a pharmaceutical composition for the inhibition of cancer metastasis, more precisely, a novel pharmaceutical composition against cancer metastasis comprising lipocalin 2 protein, a gene encoding the protein, an expression vector containing the gene or cells transfected with the expression vector as an effective ingredient, a method for the inhibition of cancer metastasis using the composition, a diagnostic kit for the prediction of cancer metastasis, a method for the selection of a metastasis risk group using the kit, a novel pharmaceutical composition for the inhibition of cancer growth and a method for the inhibition of cancer growth using the same. The pharmaceutical composition of the present invention specifically inhibits cancer metastasis, so that it can improve the effect of cancer treatment dramatically.

Abstract: The present invention relates to an expression vector for animal cells. Specifically, the present invention relates to an expression vector, pMS vector, pSG vector and pMSG vector, including the human ?-globin 5? MAR complementary sequence or/and the transcription termination site of the gastrin gene. An expression system using an expression vector of the present invention can successfully produce recombinant proteins in various animals cells and recombinant protein having a unique structure and function.

Abstract: The present application discloses a method of reducing tumor growth that includes contacting the tumor with a tumor growth reducing effective amount of a composition comprising LK8 or LK68 protein or a functionally equivalent amino acid variant thereof and a pharmaceutically acceptable carrier thereof to a subject having tumor.

Abstract: The present invention relates to mammalian expression vectors including nuclear matrix attachment region of human interferon ?, and more particularly to pPGM-1, pPGM-2 and pPGM-3 including nuclear matrix attachment region of interferon ? gene. Those expression vectors confer position independent expression of the introduced foreign gene, thus increasing the frequency of colonies which efficiently express the recombinant protein.

Abstract: The present invention relates to an anticancer or an anti-metastatic agent for gene therapy, more precisely, an anticancer or an anti-metastatic agent for gene therapy containing a gene carrier or cells harboring human apolipoprotein (a) kringle KIV9-KIV10-KV (LK68) or KV (LK8) gene as an effective ingredient, and a treatment method for cancer using the same. The agent for gene therapy of the present invention has an inhibiting effect on the growth and the metastasis of a tumor, so it can be effectively used for the prevention and the treatment of various solid tumors as a metastasis inhibitor or a therapeutic agent for primary tumors.

Abstract: The present application discloses a method of reducing tumor growth that includes contacting the tumor with a tumor growth reducing effective amount of a composition comprising LK8 or LK68 protein or a functionally equivalent amino acid variant thereof and a pharmaceutically acceptable carrier thereof to a subject having tumor.

Abstract: The present invention relates to mammalian expression vectors including nuclear matrix attachment region of human interferon &bgr;, and more particularly to pPGM-1, pPGM-2 and pPGM-3 including nuclear matrix attachment region of interferon &bgr; gene. Those expression vectors confer position independent expression of the introduced foreign gene, thus increasing the frequency of colonies which efficiently express the recombinant protein.

Abstract: The present invention relates to a expression vector for animal cells. Specifically, the present invention relates to a expression vector, pMS vector, pSG vector and pMSG, vector, including the human &bgr;-globin 5′ MAR complementary sequence or/and the transcription termination site of gastrin gene. An expression system using the expression vector of the present invention can successfully produce recombinant proteins in various animals cells and recombinant protein having a unique structure and function.